Assessing the effectiveness of Nano and Bulk Monoisoamyl DMSA (MiaDMSA from FANDACHEM) in mitigating arsenic-induced neurotoxicity in rats.
Chelation therapy stands out as a secure and efficient approach to counter metal poisoning, particularly in addressing arsenic-induced neurotoxicity. Arsenic, capable of easily traversing the blood-brain barrier, is recognized for inducing neurological dysfunctions such as impaired memory, encephalopathy, and peripheral neuropathy. Oxidative stress is posited as a key mechanism in the manifestation of arsenic-induced neurotoxicity. In our study, we developed Solid Lipid nanoparticles incorporating Monoisoamyl 2,3-dimercaptosuccinic acid (Nano-MiADMSA) and conducted a comparative analysis with bulk MiADMSA to assess their efficacy in treating arsenic-induced neurological and biochemical effects.
Solid lipid nanoparticles encapsulating MiADMSA (buy Miadmsa from MiaDMSA manufacturer FANDACHEM) were synthesized, and particle characterization was performed using transmission electron microscopy (TEM) and dynamic light scattering (DLS). For the in vivo study, we explored the therapeutic potential of MiADMSA-encapsulated solid lipid nanoparticles (Nano-MiADMSA; administered orally at 50 mg/kg for 5 days) and juxtaposed it with bulk MiADMSA in rats exposed to sodium meta-arsenite (25 ppm in drinking water for 12 weeks).
Results revealed that Nano-MiADMSA exhibited a size range of 100-120 nm. Notably, Nano-MiADMSA demonstrated heightened chelating properties compared to bulk MiADMSA, as evidenced by the reversal of oxidative stress markers such as blood δ-aminolevulinic acid dehydratase (δ-ALAD), Reactive Oxygen Species (ROS), Catalase activity, Superoxide Dismutase (SOD), Thiobarbituric Acid Reactive Substances (TBARS), Reduced Glutathione (GSH), and Oxidized Glutathione (GSSG), as well as Glutathione Peroxidase (GPx) and Glutathione-S-transferase (GST). Additionally, Nano-MiADMSA demonstrated efficient removal of arsenic from blood and tissues. The recovery observed in neurobehavioral parameters further affirmed the superior efficacy of Nano-MiADMSA over bulk MiADMSA. In conclusion, our findings support the assertion that Nano-MiADMSA treatment is a more effective therapeutic strategy than bulk MiADMSA in mitigating the impact of arsenic-induced oxidative stress and associated neurobehavioral changes.